Evidence map›Paper›PMID 35896888›Full record

ArticleOphthalmology and therapy2022

Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology.

Noura Al Qassimi, Igor Kozak, Maysoon Al Karam, Piergiorgio Neri, Patricio M Aduriz-Lorenzo, Alaa Attawan, Mohamed Awadalla, Ahmed El Khashab, Mohamed Abdul-Nabi, Ammar Safar and 6 more

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. A meta-analysis of clinical outcomes in diabetic macular edema.Advances in ophthalmology practice and research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Noura Al QassimiSheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates. n.alqassimi@gmail.com.
Igor KozakMoorfields Eye Hospital, Abu Dhabi, United Arab Emirates.
Maysoon Al KaramYAS Clinic, Abu Dhabi, United Arab Emirates.
Piergiorgio NeriCleveland Clinic, Abu Dhabi, United Arab Emirates.
Patricio M Aduriz-LorenzoDubai Hospital, Dubai, United Arab Emirates.
Alaa AttawanTawam Hospital, Al Ain, United Arab Emirates.
Mohamed AwadallaAl Qassimi Hospital, Sharjah, United Arab Emirates.
Ahmed El KhashabEye Consultants Center Dubai, Dubai, United Arab Emirates.
Mohamed Abdul-NabiSheikh Shakhbout Medical City in Association With Mayo Clinic, Abu Dhabi, United Arab Emirates.
Ammar SafarMoorfields Eye Hospital, Dubai, United Arab Emirates.
Hanan Al ShamsiTawam Hospital, Al Ain, United Arab Emirates.
Prasan RaoMedcare Eye Centre, Dubai, United Arab Emirates.
Madhav RaoBurjeel Hospital, Abu Dhabi, United Arab Emirates.
Amr FaridMagrabi Eye Hospital, Dubai, United Arab Emirates.
Avinash GurbaxaniMoorfields Eye Hospital, Dubai, United Arab Emirates.
Emirates Society of Ophthalmology
Tawam Hospital · AEDubai Hospital · AEDubai Medical College · AEKhalifa University of Science and Technology · AEMafraq Hospital · AEOasis Hospital · AEShaikh Khalifa Medical City · AESheikh Shakhbout Medical City · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the United Arab Emirates, retinopathy has been shown to be present in 19% of the diabetic population, with diabetes identified in up to 40% of individuals aged over 55 years. Despite the prevalence of diabetic retinal diseases, there are no unified national guidelines on the management of diabetic macular edema (DME). These published guidelines are based on evidence taken from the literature and published trials of therapies, and consensus opinion of a representative expert panel with an interest in this condition, convened by the Emirates Society of Ophthalmology. The aim is to provide evidence-based, clinical guidance for the best management of different aspects of DME, with a special focus on vision-threatening diabetic retinopathy. Treatment should be initiated in patients with best-corrected visual acuity 20/30 or worse, and/or features of DME as seen on optical coherence tomography (OCT) with central retinal thickness (CRT) of at least 300 μm or in symptomatic patients with vision better than 20/25, and/or CRT less than 300 μm where there are OCT features consistent with center-involving macular edema. The treatment of DME is effective irrespective of glycated hemoglobin (HbA1c) level, and treatment must not be denied or delayed in order to optimize systemic parameters. All ophthalmic treatment options should be discussed with the patient for better compliance and expectations. Non-center-involving DME can be initially observed until progression toward the center is documented. Macular laser no longer has a primary role in center-involving DME, and anti-vascular endothelial growth factor (anti-VEGF) therapy should be considered as first-line treatment for all patients, unless contraindicated. If anti-VEGF is contraindicated, a steroid dexamethasone implant can be considered for first-line treatment. Recommendations for the treatment of DME in special circumstances and in relapsing and refractory DME are also discussed.

Indexed as

Anti-VEGFConsensus guidelinesCorticosteroidsDiabetesIntravitreal injectionMacular edemaVascular endothelial growth factor

Identifiers

PMID35896888
PMCPMC9437198
OpenAlexW4288068542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.